UCB SA UCBJF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $233.45
- Day Range
- $238.54–238.54
- 52-Week Range
- $228.94–345.39
- Bid/Ask
- $146.67 / $349.05
- Shares Outstanding
- 190.66M
- Market Cap
- $45.41B
- Volume/Avg
- 17 / 537
Key Statistics
- Price/Earnings (Normalized)
- 16.74
- Price/Sales
- 4.55
- Dividend Yield (Trailing)
- 0.71%
- Dividend Yield (Forward)
- 0.71%
- Dividend Payment Schedule
- May
- Total Yield
- 1.05%
Company Profile
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 10,117
- Website
- https://www.ucb.com
Competitors
Valuation
|
Metric
|
UCBJF
|
GMAB
|
ARGX
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.74 | 21.72 | 35.48 |
Price/Book Value | 3.34 | 3.64 | 7.14 |
Price/Sales | 4.55 | 5.45 | 12.28 |
Price/Cash Flow | 15.95 | 22.16 | 41.04 |
Price/Earnings
UCBJF
GMAB
ARGX
Financial Strength
|
Metric
|
UCBJF
|
GMAB
|
ARGX
|
|---|---|---|---|
Quick Ratio | 0.82 | 2.44 | 4.52 |
Current Ratio | 1.20 | 2.46 | 5.12 |
Interest Coverage | 27.73 | 3.88 | 411.30 |
Quick Ratio
UCBJF
GMAB
ARGX
Profitability
|
Metric
|
UCBJF
|
GMAB
|
ARGX
|
|---|---|---|---|
Return on Assets (Normalized) | 13.57% | 11.74% | 22.69% |
Return on Equity (Normalized) | 23.59% | 21.07% | 30.35% |
Return on Invested Capital (Normalized) | 19.03% | 14.75% | 24.38% |
Return on Assets
UCBJF
GMAB
ARGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|DXfL$w | LOCK|NK%% | $128B | |||
| Moderna Inc
MRNA
| LOCK|?^@s#>< | LOCK|?DS | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|rClv$!? | LOCK|<L$>V | $76B | |||
| argenx SE ADR
ARGX
| LOCK|^G#Bc@$ | LOCK|L# | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!$@SSl | LOCK|DVl | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!$TlBt@ | LOCK|kJJ? | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Tx<g!^nj | LOCK|fyWQ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|%@?C%!K | LOCK|>s | $24B | |||
| Incyte Corp
INCY
| LOCK|&^>qTt | LOCK|<& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|S%c@F@N | LOCK|Rj | $15B |
United States